Generation Of Protective Immunity Against Severe Influenza Disease In Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$1,630,970.00
Summary
Hospitalisation and death rates from influenza are high in the Indigenous population, especially when a new virus emerges. There is an urgent need for a vaccine that protects against all influenza strains. T cells recognising conserved viral regions elicit such protection. As T cells are restricted by proteins called HLAs, which vary across ethnicities, we will define T cell regions for HLAs prominent in Indigenous Australians and define how to generate protective immunity against influenza.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0453256
Funder
Australian Research Council
Funding Amount
$512,573.00
Summary
National Positron Beamline Facility. We shall construct an experimental facility for the study of positron interactions with atoms, molecules and condensed matter. It will
- Provide a unique Australian facility for the study of positron interactions with matter
- Provide benchmark data for low energy positron interactions with atoms and molecules and a reference point for theoretical calculations
- Provide Australian materials scientists with a new tool for the development of novel material ....National Positron Beamline Facility. We shall construct an experimental facility for the study of positron interactions with atoms, molecules and condensed matter. It will
- Provide a unique Australian facility for the study of positron interactions with matter
- Provide benchmark data for low energy positron interactions with atoms and molecules and a reference point for theoretical calculations
- Provide Australian materials scientists with a new tool for the development of novel materials and thin film technology
- Provide new insight on the mechanisms of positron binding to matter
- Address a National Research Priority: Frontier Technologies for Building and Transforming Australian Industries.
Read moreRead less
Diseases caused by the pneumococcus represent the largest cause of vaccine preventable death in the world today, mainly pneumonia and meningitis. In 2011, 16 developing countries will introduce pneumococcal conjugate vaccines, none in east Asia. Lack of research has been a major barrier to their use in the region. We have established an international centre of excellence in the field and we seek support to extend the capacity of this group and to transfer the technology to Vietnam.
Impact Of DTP Schedules On The Immunogenicity Of 2 Doses Of 13v-PCV Followed By An Early Booster
Funder
National Health and Medical Research Council
Funding Amount
$2,651,687.00
Summary
This project aims to come up with a vaccination schedule to make pneumococcal vaccines more effective and affordable for Fiji and other developing countries. We will evaluate schedules involving a 2 dose primary series in early infancy with a booster at 9 months of age. We will compare the immune responses to 3 different primary series and 2 booster options. The results of this project will be used to provide advice, at global and country levels, regarding introduction of pneumococcal vaccines.